Natalizumab for the treatment of relapsing multiple sclerosis

QR Code

Natalizumab for the treatment of relapsing multiple sclerosis

Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an &alpha;4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Richard A Rudick, Michael A Panzara
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2008
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/4b8f45d87cdf40a88c04b2ca437e248d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Risk acceptance in multiple sclerosis patients on natalizumab treatment.
par: Carmen Tur, et autres
Publié: (2013)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
par: Damiano Paolicelli, et autres
Publié: (2009)

The use of natalizumab for multiple sclerosis
par: Brandstadter R, et autres
Publié: (2017)

Natalizumab in the treatment of Crohn&rsquo;s disease
par: Danila Guagnozzi, et autres
Publié: (2008)

Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
par: Pietro Iaffaldano, et autres
Publié: (2012)

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
par: Lars Börnsen, et autres
Publié: (2012)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
par: Michael Auer, et autres
Publié: (2021)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
par: Cohan S
Publié: (2016)

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
par: Herold TR, et autres
Publié: (2012)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
par: Nooka A, et autres
Publié: (2013)

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
par: Thomas F Benkert, et autres
Publié: (2012)

Early stage and long term treatment of multiple sclerosis with interferon-&beta;
par: Angela Applebee, et autres
Publié: (2009)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
par: Reuss R
Publié: (2013)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
par: Lugaresi A, et autres
Publié: (2013)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
par: Anne Waschbisch, et autres
Publié: (2011)

Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
par: Clara de Andrés, et autres
Publié: (2012)

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant
par: Binyamin O, et autres
Publié: (2015)

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant [Corrigendum]
par: Binyamin O, et autres
Publié: (2018)

Comparison of familial and sporadic multiple sclerosis in Iraqi patients
par: Hasan A. Al-hamadani, et autres
Publié: (2021)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
par: Julie A Murphy, et autres
Publié: (2010)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
par: Slobodan M Jankovic
Publié: (2010)

Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
par: Clara G. Chisari, et autres
Publié: (2021)

Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
par: Aaron H. Morris, et autres
Publié: (2020)

Measuring treatment response to advance precision medicine for multiple sclerosis
par: Peter A. Calabresi, et autres
Publié: (2021)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
par: Kerstin Hellwig, et autres
Publié: (2021)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
par: Mohammadi R, et autres
Publié: (2021)

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action
par: Damal K, et autres
Publié: (2013)

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
par: Henrik Lund, et autres
Publié: (2013)

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
par: Mark Lyksborg, et autres
Publié: (2014)

Identification of Peptide Mimotope Ligands for Natalizumab
par: Laura E. Ruff, et autres
Publié: (2018)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
par: Dubey D, et autres
Publié: (2015)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
par: Fabricio Gonz&aacute;lez-Andrade, et autres
Publié: (2010)

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
par: Elsbernd PM, et autres
Publié: (2021)

The effect of Benson relaxation technique on fatigue of patients diagnosed with multiple sclerosis
par: Abeer Hisham Alzaghmouri, et autres
Publié: (2021)

Pain syndrome patterns and their characteristics in multiple sclerosis patients
par: M.I. Bozhenko
Publié: (2021)

Vestibular Evoked Myogenic Potential in Multiple Sclerosis (MS)
par: Alaa Ameen Hamed, et autres
Publié: (2020)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
par: Franz DN
Publié: (2013)

The role of B cells in systemic sclerosis
par: Marina D Kraaij, et autres
Publié: (2008)

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
par: Davis T, et autres
Publié: (2013)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
par: Gupta VA, et autres
Publié: (2013)